Evofem Biosciences (EVFM) Slowly Recovering After Falling 95%

If Evofem’s stock followed plunging S&P by at least 20% it would lose since March 2022. Last week NASDAQ: EVFM started surging after Supreme Court decided to strike down Roe v. Wade.

To decrease abortion and control birth rates Evofem’s non-hormonal gel could lead to controlling pH levels. That’s why experts speculate that EVFM is soaring due to this fact.

At the time of writing the stock is trading at $0.66 after jumping drastically by 78% in premarket. This bounce could be just made out of assumptions. The company is still bearing income loss for several years. To achieve a high revenue level Evofem needs more products to market.